Wave Life Sciences, Inc. (WVE) Form 10-Q — Oct 27, 2026
Wave Life Sciences filed its Q3 2026 10-Q reporting a net loss of $61.9 million on revenue of $13.2 million, with revenue up 73% year-over-year driven by GSK collaboration payments including a new $12.0 million candidate-selection milestone. Nine-month revenue was $53.7 million versus $25.5 million a year ago, boosted by $35.9 million in recognized AATD deferred revenue after regaining full rights to WVE-006 from GSK. The company holds $431.0 million in cash, cash equivalents and marketable securities, which management says funds operations for at least the next twelve months. The quarter also reflects the completed Redomiciliation making Wave Life Sciences, Inc.
Key figures
- Revenue
- 13158000
- Total Debt
- 0
- Revenue Yoy
- 73% (Q3 2026 vs Q3 2025: $13.2M vs $7.6M)
- Total Assets
- 507930000
- Cash Position
- 431000000
- Shares Outstanding
- 197228968
- Q3 2025 revenue
- 7608000
- Q3 2026 revenue
- 13158000
- Q3 g and a expense
- 25362000
- Q3 r and d expense
- 53843000
- Gsk milestone payment
- $12.0 million (candidate selection milestone, recorded in Q3 2026)
- Nine month revenue 2026
- 53676000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.